Patient Dosing Begins in Phase 1/2a Trial of Oral NMD670

Patient Dosing Begins in Phase 1/2a Trial of Oral NMD670

298305

Patient Dosing Begins in Phase 1/2a Trial of Oral NMD670

Patient dosing has begun in a Phase 1/2a clinical trial of NMD670, an investigational oral therapy by NMD Pharma aiming to improve motor abilities and quality of life for people with myasthenia gravis (MG). “We are pleased to announce the dosing of the first myasthenia gravis patient today with our lead development candidate, NMD670. This represents a significant milestone in this study and for NMD Pharma,” Thomas Holm Pedersen, the company’s CEO, said in a press…

You must be logged in to read/download the full post.